Puerarin Combined with Nicorandil is More Effective in Treating Coronary Heart Disease and Angina Pectoris

Patients with coronary heart disease and angina pectoris were divided into two groups (control and treatment) of 54 patients per group. The control group received puerarin, whereas the treatment group received puerarin plus nicorandil. Therapeutic outcomes of two treatments were compared by assessing lower left ventricular end systolic diameter, lower left ventricular end diastolic diameter, higher left ventricular ejection fraction, duration of angina pectoris, number of angina attacks, dosage of nitroglycerin needed, plasma viscosity, whole blood viscosity, fibrinogen level, pro-inflammatory markers, as well as 36-item Short Form Survey scores. The total therapeutic rate was better in the group receiving both puerarin and nicorandil than puerarin alone. No difference was discovered in the incidence of adverse reactions between the two groups. This led us to conclude that puerarin combined with nicorandil is more effective in treating coronary heart disease and angina pectoris and can improve cardiac functions, lessen chemodynamic indexes and inflammatory reactions of angina pectoris, and promote the quality of life of patients.